Last reviewed · How we verify
RO4602522
At a glance
| Generic name | RO4602522 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (PHASE2)
- A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers (PHASE1)
- A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval (PHASE1)
- A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers (PHASE1)
- A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers (PHASE1)
- Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation. (PHASE2)
- Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO4602522 CI brief — competitive landscape report
- RO4602522 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI